Parkinson’s disease (PD) is a progressive neurodegenerative disorder that has been recognized for over 200 years by its clinically dominant motor system impairment. There are prominent non-motor symptoms as well, and among these, psychiatric symptoms of depression and anxiety and cognitive impairment are common and can appear earlier than motor symptoms. Although the neurobiology underlying these particular PD-associated non-motor symptoms is not completely understood, the identification of PARK genes that contribute to hereditary and sporadic PD has enabled genetic models in animals that, in turn, have fostered ever deepening analyses of cells, synapses, circuits, and behaviors relevant to non-motor psychiatric and cognitive symptoms of human PD. Moreover, while it has long been recognized that inflammation is a prominent component of PD, recent studies demonstrate that brain-immune signaling crosstalk has significant modulatory effects on brain cell and synaptic function in the context of psychiatric symptoms. This review provides a focused update on such progress in understanding the neurobiology of PD-related non-motor psychiatric and cognitive symptoms.
AbellanasMAZamarbideMBasurcoLLuquinEGarcia-GraneroMClaveroP, and others. 2019. Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions. J Neuroinflammation16(1):233.
2.
Abou-SleimanPMMuqitMMWoodNW. 2006. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci7(3):207–19.
3.
AllenAPKennedyPJDockraySCryanJFDinanTGClarkeG.2017. The Trier Social Stress Test: principles and practice. Neurobiol Stress6:113–26.
4.
Alvarez-ErvitiLCouchYRichardsonJCooperJMWoodMJ. 2011. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res69(4):337–42.
5.
BastideMFMeissnerWGPicconiBFasanoSFernagutPOFeyderM, and others. 2015. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol132:96–168.
6.
Beccano-KellyDAKuhlmannNTatarnikovIVoltaMMunsieLNChouP, and others. 2014. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci8:301.
7.
BensonDHuntleyGW. 2019. Are we listening to everything the PARK genes are telling us?J Comp Neurol527 (9):1527–40.
8.
BertonOCovingtonHE3rdEbnerKTsankovaNMCarleTLUleryP, and others. 2007. Induction of ΔFosB in the periaqueductal gray by stress promotes active coping responses. Neuron55(2):289–300.
9.
BesteCMollCKEPotter-NergerMMunchauA.2018. Striatal microstructure and its relevance for cognitive control. Trends Cogn Sci22(9):747–51.
10.
BroenMPGNarayenNEKujifMLDissanayakaNNWLeentjensAFG. 2016. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord31:1125–33.
11.
BurtonACNakamuraKRoeschMR. 2015. From ventral-medial to dorsal-lateral striatum: neural correlates of reward-guided decision-making. Neurobiol Learn Mem117:51–9.
12.
CaoMWuYAshrafiGMcCartneyAJWheelerHBushongEA, and others. 2017. Parinson Sac domain mutation in synaptojanin 1 impairs clathrin uncoating at synapses and triggers dystrophic changes in dopaminergic axons. Neuron93:882–96.
13.
ChenCSotoGDumrongprechachanVBannonNKangSKozorovitskiyY, and others. 2020. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations. Elife9:e58997. doi:10.7554/eLife.58997
14.
ChengH-CUlaneCMBurkeRE. 2010. Clinical progression in Parkinson’s disease and the neurobiology of axons. Ann Neurol67:715–25.
15.
ChesseletMFRichterFZhuCMagenIWatsonMBSubramaniamSR. 2012. A progressive mouse model of Parkinson’s disease: the Thy1-aSyn (“Line 61”) mice. Neurotherapeutics9(2):297–314.
16.
ChristoffelDJGoldenSAWalshJJGuiseKGHeshmatiMFriedmanAK, and others. 2015. Excitatory transmission at thalamo-striatal synapses mediates susceptibility to social stress. Nat Neurosci18(7):962–4.
17.
ChungJYParkHRLeeSJLeeSHKimJSJungYS, and others. 2013. Elevated TRAF2/6 expression in Parkinson’s disease is caused by the loss of Parkin E3 ligase activity. Lab Invest93(6):663–76.
Cruz-PereiraJSReaKNolanYMO’LearyOFDinanTGCryanJF. 2020. Depression’s unholy trinity: dysregulated stress, immunity, and the microbiome. Annu Rev Psychol71:49–78.
21.
DawsonTMKoHSDawsonVL.2010. Genetic animal models of Parkinson’s disease. Neuron66(5):646–61.
22.
DenistonCKSalogiannisJMatheaSSneadDMLahiriIMatyszewskiM, and others. 2020. Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction. Nature588:344–9.
23.
Di FilippoMPicconiBTantucciMGhiglieriVBagettaVSgobioC, and others. 2009. Short-term and long-term plasticity at corticostriatal synapses: implications for learning and memory. Behav Brain Res199(1):108–18.
24.
DiogenesMJDiasRBRomboDMVicente MirandaHMaiolinoFGuerreiroP, and others. 2012. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci32(34):11750–62.
25.
DumanRSMonteggiaLM. 2006. A neurotrophic model for stress-related mood disorders. Biol Psychiatry59(12): 1116–27.
26.
DzamkoNGeczyCLHallidayGM. 2015. Inflammation is genetically implicated in Parkinson’s disease. Neuroscience302:89–102.
ErroRPicilloMVitaleCAmboniMMocciaMSantangeloG, and others. 2016. The non-motor side of the honeymoon period of Parkinson’s disease and its relationship with quality of life: a 4-year longitudinal study. Eur J Neurol23(11):1673–9.
29.
FaggianiEBenazzouzA.2017. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: from history ot the interaction with the monoaminergic systems. Prog Neurobiol151:139–56.
30.
FlemingSMSalcedoJFernagutP-ORockensteinEMasliahELevineMS, and others. 2004. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci24:9434–440.
31.
FleshnerMFrankMMaierSF. 2017. Danger signals and inflammasomes: stress-evoked sterile inflammation in mood disorders. Neuropsychopharmacology42(1):36–45.
32.
FrakesAEFerraiuoloLHaidet-PhillipsAMSchmelzerLBraunLMirandaCJ, and others. 2014. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron81(5):1009–23.
33.
FrancisTCChandraRFriendDMFinkelEDayritGMirandaJ, and others. 2015. Nucleus accumbens medium spiny neuron subtypes mediate depression-related outcomes to social defeat stress. Biol Psychiatry77(3):212–22.
34.
GareauMG. 2016. Cognitive function and the microbiome. Int Rev Neurobiol131:227–46.
35.
GergesNZBackosDSEstebanJA. 2004. Local control of AMPA receptor trafficking at the postsynaptic terminal by a small GTPase of the Rab family. J Biol Chem279(42): 43870–8.
36.
GiassonBIDudaJEQuinnSMZhangBTrojanowskiJQLeeVM. 2002. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron34(4):521–33.
37.
GokceOStanleyGMTreutleinBNeffNFCampJGMalenkaRC, and others. 2016. Cellular taxonomy of the mouse striatum as revealed by single-cell RNA-seq. Cell Rep16:1126–37.
38.
GoldenSACovingtonHE3rdBertonORussoSJ. 2011. A standardized protocol for repeated social defeat stress in mice. Nat Protoc6(8):1183–91.
39.
GrahamDRSidhuA.2010. Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res88(8):1777–83.
40.
GuevaraCAMatikainen-AnkneyBAKezunovicNLeClairKConwayAPMenardC, and others. 2020. LRRK2 mutation alters behavioral, synaptic, and nonsynaptic adaptations to acute social stress. J Neurophysiol123(6): 2382–9.
41.
GultekinBKOzdilekbBestepeEE. 2014. Social phobia in Parkinson’s disease: prevalence and risk factors. Neuropsychiatr Dis Treat10:829–34.
42.
GustafssonHNordstromANordstromP.2015. Depression and subsequent risk of Parkinson disease: a nationwide cohort study. Neurology84(24):2422–9.
43.
HemmerleAMHermanJPSeroogyKB. 2012. Stress, depression and Parkinson’s disease. Exp Neurol233(1):79–86.
44.
HoMS. 2019. Microglia in Parkinson’s disease. Adv Exp Med Biol1175:335–53.
45.
HodesGEKanaVMenardCMeradMRussoSJ. 2015. Neuroimmune mechanisms of depression. Nat Neurosci18(10):1386–93.
46.
HodesGEPfauMLLeboeufMGoldenSAChristoffelDJBregmanD, and others. 2014. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci U S A111(45):16136–41.
47.
HornykiewiczO. 1974. The mechanisms of action of l-dopa in Parkinson’s disease. Life Sci15(7):1249–59.
48.
HunotSBruggBRicardDMichelPPMurielMPRubergM, and others. 1997. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci U S A94(14):7531–6.
49.
ImamuraKHishikawaNSawadaMNagatsuTYoshidaMHashizumeY.2003. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol106(6):518–26.
50.
JayasooriyaRGLeeKTLeeHJChoiYHJeongJWKimGY. 2014. Anti-inflammatory effects of beta-hydroxyisovalerylshikonin in BV2 microglia are mediated through suppression of the PI3K/Akt/NF-kB pathway and activation of the Nrf2/HO-1 pathway. Food Chem Toxicol65:82–9.
51.
JodoEInabaHNariharaISotoyamaHKitayamaEYabeH, and others. 2019. Neonatal exposure to an inflammatory cytokine, epidermal growth factor, results in the deficits of mismatch negativity in rats. Sci Rep9(1):7503.
52.
KastenMMarrasCKleinC.2017. Nonmotor signs in genetic forms of Parkinson’s disease. Int Rev Neurobiol133:129–78.
53.
KauerJAMalenkaRC. 2007. Synaptic plasticity and addiction. Nat Rev Neurosci8(11):844–58.
54.
KesselsHWMalinowR.2009. Synaptic AMPA receptor plasticity and behavior. Neuron61(3):340–50.
55.
KettLRBoassaDHoCC-YRideoutHJTeradaMEllismanM, and others. 2012. LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet21:890–9.
56.
KleinCWestenbergerA.2012. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med2(1):a008888.
57.
KooJWRussoSJFergusonDNestlerEJDumanRS. 2010. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A107(6):2669–74.
58.
KrishnanVNestlerEJ. 2008. The molecular neurobiology of depression. Nature455(7215):894–902.
59.
KueblerUZuccarella-HacklCArpagausAWolfJMFarahmandFvon KanelR, and others. 2015. Stress-induced modulation of NF-kappaB activation, inflammation-associated gene expression, and cytokine levels in blood of healthy men. Brain Behav Immun46:87–95.
60.
LamHAWuNCelyIKellyRLHeanSRichterF, and others. 2011. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressin human a-synuclein. J Neurosci Res89:1091–102.
61.
LangstonJW. 2006. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol59(4):591–6.
62.
LautenschlagerJKaminskiCFKaminski SchierleGS. 2017. Alpha-synuclein—regulator of exocytosis, endocytosis, or both?Trends Cell Biol27(7):468–79.
63.
LiddelowSAGuttenplanKAClarkeLEBennettFCBohlenCJSchirmerL, and others. 2017. Neurotoxic reactive astrocytes are induced by activated microglia. Nature541:481–7.
64.
LisPBurelSStegerMMannMBrownFDiezF, and others. 2018. Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson’s disease kinase. Biochem J475:1–22.
65.
LeinESHawrylyczMJAoNAyresMBensingerABernardA, and others. 2007. Genome-wide atlas of gene expression in the adult mouse brain. Nature445(7124):168–76.
66.
LiYNiuMZhaoAKangWChenZLuoN, and others. 2019. CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease. J Neuroinflammation16(1):263.
LimYKehmVMLeeEBSoperJHLiCTrojanowskiJQLeeVM. 2011. alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci31(27):10076–87.
69.
LinHLLinHCChenYH. 2014. Psychiatric diseases predated the occurrence of Parkinson disease: a retrospective cohort study. Ann Epidemiol24(3):206–13.
70.
LiuTZhangLJooDSunSC. 2017. NF-kappaB signaling in inflammation. Signal Transduct Target Ther2:17023.
71.
LukKCKehmVCarrollJZhangBO’BrienPTrojanowskiJQ, and others. 2012. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science338(6109):949–53.
72.
LurieDI. 2018. An integrative approach to neuroinflammation in psychiatric disorders and neuropathic pain. J Exp Neurosci12:1179069518793639.
73.
MagalhaesCAFerreiraCNLouresCMGFragaVGChavesACOliveiraACR, and others. 2018. Leptin, hsCRP, TNF-alpha and IL-6 levels from normal aging to dementia: relationship with cognitive and functional status. J Clin Neurosci56:150–5.
74.
MagenIChesseletM-F.2011. Mouse models of cognitive deficits due to alpha-synuclein pathology. J Parkinsons Dis1:217–27.
75.
MagenIFlemingSMZhuCGarciaECCardiffKMDinhD, and others. 2012. Cognitive deficits in a mouse model of pre-manifest Parkinson’s disease. Eur J Neurosci35:870–82.
76.
Matikainen-AnkneyBAKezunovicNMenardCFlaniganMEZhongYRussoSJ, and others. 2018. Parkinson’s disease-linked LRRK2-G2019S mutation alters synaptic plasticity and promotes resilience to chronic social stress in young adulthood. J Neurosci38(45):9700–11.
77.
Matikainen-AnkneyBAKezunovicNMesiasRETianYWilliamsFMHuntleyGW, and others. 2016. Altered development of synapse structure and function in striatum caused by Parkinson’s disease–linked LRRK2-G2019S mutation. J Neurosci36(27):7128–41.
78.
MattaSVan KolenKda CunhaRvan den BogaartGMandemakersWMiskiewiczK, and others. 2012. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron75(6):1008–21.
79.
MayeuxRSternYCoteLWilliamsJB. 1984. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology34(5):642–6.
80.
MenardCHodesGERussoSJ. 2016. Pathogenesis of depression: insights from human and rodent studies. Neuroscience321:138–62.
81.
MenardCPfauMLHodesGEKanaVWangVXBouchardS, and others. 2017. Social stress induces neurovascular pathology promoting depression. Nat Neurosci20(12):1752–60.
82.
MogiMHaradaMKondoTRiedererPInagakiHMinamiM, and others. 1994. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett180(2):147–50.
83.
MogiMHaradaMNarabayashiHInagakiHMinamiMNagatsuT.1996. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett211(1):13–6.
84.
MonteggiaLMBarrotMPowellCMBertonOGalanisVGemelliT, and others. 2004. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A101(29):10827–32.
85.
MoorePAHershEV. 2019. Analgesic therapy in dentistry: from a letter to the editor to an evidence-base review. Dent Clin North Am63(1):35–44.
MunsieLNMilnerwoodAJSeiblerPBeccano-KellyDATatarnikovIKhindaJ, and others. 2015. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson’s disease VPS35 mutation p.D620N. Hum Mol Genet24(6):1691–703.
88.
NagatsuTMogiMIchinoseHTogariA.2000. Cytokines in Parkinson’s disease. J Neural Transm Suppl58:143–51.
89.
NagayamaHMaedaTUchiyamaTHashimotoMNomotoNKanoO, and others. 2017. Anhedonia and its correlation with clinical aspects in Parkinson’s disease. J Neurol Sci372:403–7.
90.
NemaniVMLuWBergeVNakamuraKOnoaBLeeMK, and others. 2010. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron65(1):66–79.
91.
NguyenMKraincD.2018. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease. Proc Natl Acad Sci U S A115(21):5576–81.
92.
PanPYLiXWangJPowellJWangQZhangY, and others. 2017. Parkinson’s disease–associated LRRK2 hyperactive kinase mutant disrupts synaptic vesicle trafficking in ventral midbrain neurons. J Neurosci37(47):11366–76.
93.
ParisiadouLYuJSgobioCXieCLiuGSunL, and others. 2014. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci17(3):367–76.
94.
ParkinsonJ. 2002. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci14(2):223–36.
95.
PaumierKLSukoff RizzoSJBergerZChenYGonzalesCKaftanE, and others. 2013. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson’s disease. PLoS One8(8):e70274.
96.
PellecchiaMTSantangeloGPicilloMPivonelloRLongoKPivonelloC, and others. 2013. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson’s disease patients. J Neurol260(2):438–44.
97.
PeruginiADitterichJShaikhAGKnowltonBJBassoMA. 2018. Paradoxical decision-making: a framework for understanding cognition in Parkinson’s disease. Trends Neurosci41(8):512–25.
98.
PetersonDAElliottCSongDDMakeigSSejnowskiTJPoiznerH.2009. Probabilistic reversal learning is impaired in Parkinson’s disease. Neurosci163:1092–101.
99.
PfefferSR. 2018. LRRK2 and Rab GTPases. Biochem Soc Trans46(6):1707–12.
100.
PireddaRDesmaraisPMasellisMGasca-SalasC.2020. Cognitive and psychiatric syptoms in genetically determined Parkison’s disease: a systematic review. Eur J Neurol27:229–34.
101.
PoeweWSeppiKTannerCMHallidayGMBrundinPVolkmannJ, and others. 2017. Parkinson disease. Nat Rev Dis Primers3:17013.
102.
PontoneGMDissanaykaNApostolovaLBrownRGDobkinRDujardinK, and others. 2019. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease. NPJ Parkinsons Dis5:30.
103.
ReynoldsGOHannaKKNeargarderSCronin-GolombA.2017. The relation of anxiety and cognition in Parkinson’s disease. Neuropsychology31(6):596–604.
104.
RobbinsTWCoolsR.2014. Cognitive deficits in Parkinson’s disease: a cognitive neuroscience perspective. Mov Disord29(5):597–607.
105.
RoodveldtCLabrador-GarridoAGonzalez-ReyELachaudCCGuilliamsTFernandez-MontesinosR, and others. 2013. Preconditioning of microglia by alpha-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS One8(11):e79160.
106.
RussoIBertiGPlotegherNBernardoGFilogranaRBubaccoL, and others. 2015. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-kappaB p50 signaling in cultured microglia cells. J Neuroinflammation12:230.
107.
RussoIDi BenedettoGKaganovichADingJMercatelliDMorariM, and others. 2018. Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4. J Neuroinflammation15(1):297.
108.
RussoSJNestlerEJ. 2013. The brain reward circuitry in mood disorders. Nat Rev Neurosci14(9):609–25.
SanstrumBJGooBHoldenDZYDelgadoDDNguyenTPNLeeKD, and others. 2020. Fluctuation imaging of LRRK2 reveals that the G2019S mutation alters spatial and membrane dynamics. Molecules25(11):2561.
111.
SavicaRRoccaWAAhlskogJE. 2010. When does Parkinson disease start?Arch Neurol67(7):798–801.
112.
SawadaMImamuraKNagatsuT.2006. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl (70):373–81.
113.
SchragATaddeiRN. 2017. Depression and anxiety in Parkinson’s disease. Int Rev Neurobiol133:623–55.
114.
SeidelKMahlkeJSiswantoSKrugerRHeinsenHAuburgerG, and others. 2015. The brainstem pathologies of Parkinson’s disease and dementia with Lewy bodies. Brain Pathol25(2):121–35.
115.
ShohamyD. 2011. Learning and motivation in the human striatum. Curr Opin Neurobiol21(3):408–14.
116.
SliterDAMartinezJHaoLChenXSunNFischerTD, and others. 2018. Parkin and PINK1 mitigate STING-induced inflammation. Nature561(7722):258–62.
117.
StanojlovicMPallais YllescasJPJrVijayakumarAKotzC.2019. Early sociability and social memory impairment in the A53T mouse model of Parkinson’s disease are ameliorated by chemogenetic modulation of orexin neuron activity. Mol Neurobiol56(12):8435–50.
118.
StegerMDiezFDhekneHSLisPNirujogiRSKarayelO, and others. 2017. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife6:e31012.
119.
StegerMTonelliFItoGDaviesPTrostMVetterM, and others. 2016. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife5:e12813.
120.
StellwagenDMalenkaRC. 2006. Synaptic scaling mediated by glial TNF-alpha. Nature440(7087):1054–9.
121.
StellyCEPomrenzeMBCookJBMorikawaH.2016. Repeated social defeat stress enhances glutamatergic synaptic plasticity in the VTA and cocaine place conditioning. Elife5:e15448.
122.
SweetESSaunier-ReboriBYueZBlitzerRD. 2015. The Parkinson’s disease–associated mutation LRRK2-G2019S impairs synaptic plasticity in mouse hippocampus. J Neurosci35(32):11190–5.
123.
SzegoEMGerhardtEOuteiroTFKermerP.2011. Dopamine-depletion and increased a-synuclein load induce degeneration of cortical cholinergic fibers in mice. J Neurol Sci310:90–5.
124.
TemkinPMorishitaWGoswamiDArendtKChenLMalenkaR.2017. The retromer supports AMPA receptor trafficking during LTP. Neuron94(1):74–82.e5.
125.
TerlauHSeifertW.1989. Influence of epidermal growth factor on long-term potentiation in the hippocampal slice. Brain Res484(1-2):352–6.
126.
TianYTangFLSunXWenLMeiLTangBS, and others. 2015. VPS35-deficiency results in an impaired AMPA receptor trafficking and decreased dendritic spine maturation. Mol Brain8(1):70.
127.
TufekciKUMeuwissenRGencSGencK.2012. Inflammation in Parkinson’s disease. Adv Protein Chem Struct Biol88:69–132.
VargasKJMakaniSDavisTWestphalCHCastilloPEChandraSS. 2014. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci34(28):9364–76.
130.
VoltaMBeccano-KellyDAPaschallSACataldiSMacIsaacSEKuhlmannN, and others. 2017. Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. Elife6:e28377.
131.
WangLFlemingSMChesseletM-FTacheY.2008. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport18:873–6.
132.
WangXMZhangYGLiALLongZHWangDLiXX, and others. 2016. Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson’s disease. Eur Rev Med Pharmacol Sci20(18):3853–6.
133.
WatanabeSBoucrotE.2017. Fast and ultrafast endocytosis. Curr Opin Cell Biol47:64–71.
134.
WatsonGSLeverenzJB. 2010. Profile of cognitive impairment in Parkions’s disease. Brain Pathol20:640–5.
135.
WatsonMBRichterFLeeSKGabbyLWuJMasliahE, and others. 2012. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol237(2):318–34.
WeissHDPontoneGM. 2019. “Pseudo-syndromes” associated with Parkinson disease, dementia, apathy, anxiety, and depression. Neurol Clin Pract9(4):354–9.
138.
WestABCowellRMDaherJPLMoehleMSHinkleKMMelroseHL, and others. 2014. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J Comp Neurol522:2465–80.
139.
WillnerP. 2005. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology52(2):90–110.
140.
WillnerPTowellASampsonDSophokleousSMuscatR.1987. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl)93(3):358–64.
141.
WohlebESMcKimDBSheridanJFGodboutJP. 2014. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. Front Neurosci8:447.
YeZAltenaENombelaCHousdenCRMaxwellHRittmanT, and others. 2014. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease. Brain137(Pt 4):1145–55.
144.
YunSPKaT-IPanickerNKimSMOhYParkJ-S, and others. 2018. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkison’s disease. Nat Med24:931–8.
145.
ZarrowCLynessSAMortimerJAChuiHC. 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol60:337–41.
146.
ZhangDLinJHanJ.2010. Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol7(4):243–9.
147.
ZhangYFengSNieKLiYGaoYGanR, and others. 2018. TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson’s disease. Biochem Biophys Res Commun499(4):797–802.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
